Lineage Cell Therapeutics Inc. — Director's Dealing 2013

Jun 7, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2013-06-04

Reporting Person: LICHTINGER PEDRO (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-06-04	Common Shares, no par value	P	120000	—	Acquired	126250	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-06-04	Option to Purchase Common Shares	$5.00	P	30000	Acquired	2018-06-04	Common Shares (30000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$4.60	2017-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$5.13	2016-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$5.45	2015-08-09	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$3.45	2014-08-10	Common Shares (20000)	20000	Direct

Footnotes

F1: On June 4, 2013, Mr. Lichtinger purchased 120,000 BioTime common shares and 30,000 options to purchase 30,000 common shares in a private transaction. Each common share and one quarter of each option were purchased for an aggregate price of $4.155.

F2: Does not include shares that may be acquired upon the exercise of certain stock options.

F3: 5,000 options became exercisable on September 30, 2012; December 31, 2012;and March 31, 2013. 5,000 options will become exercisable on June 30, 2013 based upon continued service on the board of directors.

F4: 5,000 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

F5: 5,000 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.

F6: 5,000 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.